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Abstract
Background: Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with
preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the
efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC).
Methods: 82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three
hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST)
was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by
the Kaplan-Meier method.
Results: Median PFS was 4.0 months (95% CI 2.311–5.689). Median OS was 11.0 months (95% CI 8.537–13.463) in this cohort.
Median PFS for first and second/third line were 7.0 months (95% CI 2.151–11.8) and 3.0 months (95% CI 1.042–4.958),
respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305–15.695) and 10.0 months (95% CI
7.295–12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR
0.36, 95% CI 0.18–0.70, p= 0.003) and death (HR 0.10, 95% CI 0.02–0.42, p= 0.002) compared with those EGFR status
unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%).
Conclusions: Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those
patients harbouring EGFR mutations, with an acceptable adverse event profile.
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Introduction
The epidermal-growth-factor receptor (EGFR) is part of a
signalling pathway that regulates tumor cell proliferation, invasion,
angiogenesis, metastasis, and apoptosis [1]. EGFR tyrosine-kinase
inhibitors (TKIs) can inhibit tumor cells by blocking the EGFR
signaling via binding to ATP binding site on the tyrosine kinase
domain of the EGFR. Activating EGFR mutations are found in
about 60% of lung adenocarcinomas in the East Asian population
and nonsmoker or former light smoker [2]. Numerous phase III
studies have shown that EGFR TKIs such as gefitinib or erlotinib
have strong anti-tumor activity and increase survival in patients
with NSCLC harboring activating EGFR mutation not only in
second and third line [3,4,5], but also in first line [2,6,7] and
maintenance treatment [8,9,10].
Icotinib hydrochloride is a new type of small molecule EGFR-
TKI, developed and patented by Zhejiang BetaPharma Co., Ltd.
(Hangzhou, Zhejiang, China, Patent No. WO2003082830). Its
chemical name is 4-((3-ethynylphenyl) amino)-6, 7-benzo-12-
crown-4- quinazoline hydrochloride. The molecular formula is
C22H21N3O4?HCl, with a small molecular weight of 427.88.
Preclinical studies showed that icotinib is a potent and specific
EGFR TKI. In vitro, icotinib could significantly inhibit the EGFR
tyrosine kinase activity at a concentration of 0.5 mM including the
EGFR (91%), EGFR (L858R) (99%), EGFR (L861Q) (96%),
EGFR (T790M) (61%) and EGFR (T790M, L858R) (61%) [11].
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In EGFR-mutated lung cancer cell lines (PC-9 and HCC827),
icotinib showed similar anti-tumor effect compared with gefitinib
[12]. In vivo, icotinib strongly inhibited the tumor growth in several
xenograft models in a dose related manner [11].
Two phase I studies evaluated the safety and tolerability of
icotinib in Chinese patients with NSCLC and other solid tumors
[13,14]. Generally, icotinib showed favorable safety and tolerabil-
ity. Mild and reversible rash, diarrhea and nausea were the main
adverse events. Notably, positive anti-tumor activities were
observed in patients with advanced NSCLC. A dose of 125 mg
or 150 mg q8h/day was recommended for phase II/III studies.
A randomized, double-blind phase III study [15] was carried
out to compare the efficacy and safety of icotinib with gefitinib in
NSCLC patients previously treated with chemotherapy (ICO-
GEN) [16]. A total of 399 patients with advanced NSCLC who
had progressed after one or two lines of chemotherapies were
randomized to receive icotinib (n = 200, 125 mg q8h) or gefitinib
(n = 199, 250 mg qd). Compared with gefitinib, icotinib provided
similar median progression-free survival (PFS, icotinib vs. gefitinib:
4.6 months vs. 3.4 months, HR 0.84, 95% CI 0.67–1.05) and
median overall survival benefit (OS, icotinib vs. gefitinib: 13.3
months vs. 13.9 months, HR 0.90, 95% CI 0.79–1.02). As with
gefitinib, biomarker analysis revealed that EGFR mutation status
was the strongest predictor for icotinib. The PFS in patients
treated with icotinib was 7.8 months in EGFR mutant subgroup
and 2.3 months in EGFR wild type population.
Based on the encouraging results of ICOGEN reported in
ASCO annual meeting in 2011, icotinib was approved for the
second or third line treatment of advanced NSCLC by the State
Food and Drug Administration of China. Gefitinib and erlotinib
have shown good efficacy as first line treatment in clinically
selected patients, while icotinib has the similar molecular structure
with gefitinib and erlotinib. In addition, icotinib is much cheaper
than gefitinib or erlotinib in China. Thus icotinib was also an
alternative choice for first line treatment in the clinic. Here, we
retrospectively analyzed the efficacy of icotinib on the treatment of
advanced NSCLC patients as first line or second/third line
treatment in clinical practice.
Patients and Methods
Ethics Statement
This study was approved by the three hospitals Review Boards:
the First and Second Affiliated Hospital of Nanjing Medical
University, and Jinling Hospital of Nanjing University School of
Medicine. Patient records were anonymized and de-identified
prior to analysis.
Patients
We conducted a retrospective search of the medical records in
the First and Second Affiliated Hospital of Nanjing Medical
University, and Jinling Hospital of Nanjing University School of
Medicine, from July 2011 to February 2013. Excluding the
patients received icotinib as forth or later lines treatment and those
whose clinical data were not available, 82 patients who received
icotinib as first line (n = 24) or second/third line (n = 58) treatment
were enrolled into our retrospective search. All these patients
received oral icotinib at a dose of 125 mg q8h/day continuously
until either a disease progression (radiographic or obvious clinical)
or severe toxicity was observed. No other chemotherapeutic drug
was administered concurrently with icotinib treatment.
Assessment of the Efficacy and Adverse Events
The Response Evaluation Criteria in Solid Tumors (RECIST)
was used to evaluate the tumor responses [17]. The evaluation was
from the patients’ original medical records and in some uncertain
cases, was re-evalatued by two radiologist (H.L & Y.J, radiology
department in the First Affiliated Hospital of Nanjing Medical
University). Objective response comprises complete response (CR)
and partial response (PR). Disease control was defined as CR, PR
or stable disease (SD). Generally, after starting with icotinib, the
first evaluation was performed at one month, and then assessed
every two months or at overt signs of progression. PFS was defined
as the period from the initial administration of icotinib to tumor
progression or death of any cause (calculated according to the
event occurred firstly). OS was defined as the span between the
start of icotinib and the date of death. Adverse events were
assessed according to Common Terminology Criteria for Adverse
Events of the National Cancer Institute (version 3.0) [18]. Clinical
data and outcomes were collected by patient medical records
search, consulting the doctors in charge, interview in the clinic and
phone calls to the patients or their relatives.
Statistical Analysis
The chi-square (x2) test was used for intergroup comparisons of
response rate and disease control rate at a significance level of 5%
(a=0.05, two-sided). PFS and OS were obtained using the
Kaplan-Meier method. Log-rank test was applied to compare the
significance between groups. Multivariate Cox-regression model
was also used to detect the hazard ratios. SPSS software package
(SPSS 17.0 Inc., Chicago, IL, USA) was applied.
Results
Patients Characteristics
A total of 82 patients who received icotinib as first (n = 24) or
second/third (n = 58) line treatment were enrolled in this
retrospective analysis. The median age of the population was 64
years. All patients were Chinese. Most patients were non-smokers,
had adenocarcinoma, stage IV disease and relatively low
performance status (Table 1). EGFR sensitive mutation was found
in 19 patients (8 in first line and 11 in second/third line) while
unknown in the remaining cases. This may due to the lack of
proper tissue and some patients were reluctant to receive the gene
detection. Five patients had diagnosed brain metastasis before they
received icotinib. In the second/third lines subset, the most
frequently used chemotherapy regimens for first/second line
treatment were pemetrexed+cisplatin/carboplatin, paclitaxel+cis-
platin/carboplatin, docetaxel+cisplatin/carboplatin and gemcita-
bine+cisplatin. Two patients received gefitinib as first line
treatment.
Response Rate
The CR, PR and SD of the whole group were 1%, 22% and
41%, respectively, a 65% overall disease control rate. Twelve of 19
patients (63%) bearing EGFR mutation experienced an objective
response, which was significantly higher than that in patients with
EGFR status unknown (7 out of 63, 11%). Higher response rates
were observed in EGFR mutation positive patients in first as well
as second/third line, while a higher disease control rate was only
seen in the first line subset (Table 2).
Progression-free Survival and Overall Survival
Median progression-free survival for the 82 patients was 4.0
months (95% CI 2.311–5.689). Patients bearing EGFR mutation
had a significantly longer PFS (9.0 months, 95% CI 3.661–14.339)
Icotinib in Non-Small-Cell Lung Cancer
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than those with EGFR status unknown (3.0 month, 95% CI
2.284–5.151, p=0.001) or the whole population (p=0.014)
(Figure 1–1). Median progression-free survival was 7.0 months
(95% CI 2.151–11.849; Figure 1–2) in first line subset and 3.0
months (95% CI 1.042–4.958, Figure 1–3) in second/third lines
subset. Consistently, patients with EGFR sensitive mutation had
longer PFS both in first line (p=0.020) and in second/third line
subgroups (p=0.034) compared with those whose EGFR status
were unknown. Multivariate analysis using Cox regression model
indicated that icotinib significantly decreased the risk of progres-
sion in patients with EGFR mutation compared with EGFR status
unkown (HR, 0.36, 95% CI 0.18–0.70, p=0.003). In patients with
EGFR mutation icotinib showed decreased risk of progression in
the first line subset, (HR, 0.21, 95% CI,0.05–0.97, p=0.046),
while insignificant/trend of risk reduction in the second/third line
subset (HR, 0.51, 95% CI 0.24–1.07, p=0.073).
Median overall survival for all patients was 11.0 months (95%
CI 8.537–13.463, Figure 2–1). Consistent with the results in PFS,
patients with EGFR mutation had statistically longer OS (not
reached) than those with EGFR status unknown (mOS 9.0
months, 95% CI 7.207–10.793, p=0.000) or the whole population
(p=0.001). This superiority was consistently observed both in first
and second/third line subsets. The median overall survival was
13.0 months (95% CI 10.305–15.695,) in the first line treatment
subgroup (Figure 2–2), and 10.0 months (95% CI 7.295–12.70) in
the second/third line (Figure 2–3). Multivariate analysis showed
that icotinib significantly reduced the risk of death in EGFR
mutation patients (HR 0.10, 95% CI 0.02–0.42, p=0.002). This
significant reduction were found both in first line (HR 0.27, 95%
CI 0.10–0.87, p=0.032) and second/third line subsets (HR 0.18,
95% CI 0.04–0.75, p=0.018).
Adverse Events
Drug related adverse event were registered in 61 of 82 patients
(74.3%, Table 3). The most common adverse events were skin-
related events and diarrhea. The incidence of acne-like rash and
diarrhea were 39.0% and 20.7% respectively. Other common
adverse events include dry skin, oral ulcer, nausea, fatigue,
elevated ALT/AST, and leukopenia. However, most of the
adverse events were grade 1 or 2, and only two grade 3 acne-
like rashes were recorded. No possible drug-related interstitial lung
disease and drug related death was noted and no patient had dose
reduction due to the adverse events. The two patients with grade 3
rash refused to reduce the dose of icotinib, and the symptoms were
alleviated through symptomatic treatment.
Discussion
Since the appearance of gefitinib and erlotinib, a novel TKI
inhibitor, icotinib, has recently showed effect in NSCLC [16]. This
relatively small retrospective study of a novel EGFR inhibitor,
icotinib, in unselected NSCLC patients from three hospitals
showed an encouraging disease control rate (65%), progression-
free survival (4.0 m) and overall survival (11.0 m). We observed
that a large proportion of patients who responded to icotinib and
longer PFS were observed in patients with EGFR mutation.
Although the OS in patients with EGFR mutation was not
reached, it was statistically longer than that in patients with EGFR
status unknown. These results suggest activity of icotinib in non-
Table 1. Patient characteristics.
First line N=24 Second/third line N=58 Total N=82 (%)
Median age 64(37–79) 65(30–80) 64
Sex
Male 9 32 41 (50)
Female 15 26 41 (50)
ECOG
0–1 7 20 27 (32.9)
2 14 28 42 (51.2)
3 3 10 13 (15.8)
Smoking history
Non-smoker 14 36 50 (60.9)
Smoker 10 22 32 (39.1)
EGFR mutation
Del 19 5 7 12 (14.6)
L858R 3 4 7 (8.5)
Not available 16 47 62 (36.9)
Clinical stage
IIIb 2 7 9 (11)
IV 22 51 73 (89)
Pathological type
Adeno 23 52 75 (91)
Squamous 1 5 6 (7.3)
Other 0 1 1 (1.7)
doi:10.1371/journal.pone.0095897.t001
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small cell lung cancer, and robust activity of icotinib in patients
with EGFR mutation.
In the second/third line subset (n = 58), the PFS were 3.0 m for
all patients, 9.0 m for EGFR mutation patients and 3.0 m for
EGFR status unknown patients. The OS was 10.0 for all patients,
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Figure 1. Progression-free survival. 1–1 shows the PFS in all
patients in this study, 1–2 shows the PFS in first line subset, 1–3 shows
the PFS in second/third line subset.
doi:10.1371/journal.pone.0095897.g001
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while the OS for EGFR mutation patients was not reached. These
results were similar with those reported in ICOGEN. In the
ICOGEN study, patients with NSCLC that progressed after one
or two lines of chemotherapies were randomized to receive
icotinib (150 mg tid) or gefitinib (250 mg qd). In the icotinib
group, the median PFS were 4.6 m for all patients and 7.8 m in
patients with EGFR mutation, and the OS was 13.3 months,
comparable with the results of gefitinib group [16,19]. Gefitinib
and erlotinib has been widely tested as second/third line treatment
for lung cancer in a series of prospective studies, such as
INTREST [3], ISEL [5], TITAN [4] and BR.21 study [20].
The PFS of tyrosine kinase inhibitors (TKIs) groups in these
studies ranged from 6.3 weeks to 3.3 months, and the OS ranged
from 5.3 to 7.6 months. Our retrospective study, based on the real
clinical practice, together with results from ICOGEN, showed that
icotinib produced a comparable benefit with gefitinib or erlotinib,
and indicated that it could be an alternative choice for patients in
second/third line treatment.
In first line subset, the PFS and OS were 7.0 m and 13.0 m for
all patients, 2.0 m and 11.0 m for EGFR status unknown patients
respectively. PFS and OS for EGFR mutation patients were not
mature. Currently, no other study reports the efficacy of icotinib as
first line treatment. Three ongoing prospective trials will give more
information about the activity of icotinib in first line
(NCT01646450, NCT01665417, NCT01719536). Patients in
our study were all Asian, 96% of them had adenocarcinoma,
63% were female, and 58% were non-smoker. These clinical
features indicate that there may be a relative high rate of EGFR
mutation. The PFS in this study was very similar with that in
patients treated with gefitinib in IPASS study [2], which enrolled
patients with clinical enrichment of EGFR mutation, including
East Asian, female, non-smoker or light smoker and adenocarci-
noma. Compared with those data in gefitinib and erlotinib studies,
the PFS and OS in this study were numerically good, considering
that there were 55 patients (67.1%) had a PS $2 in this
population. However, one should note that this is a retrospective
study and the assessment bias caused by clinical doctors may exist
while the abovementioned studies on gefitinib and erlotinib were
all prospective randomized controlled trials. In addition, the
number of cases in this study was small, thus the results may be
heavily influenced by individual cases, especially those with EGFR
active mutation.
EGFR mutation is a prognostic factor regardless of the
treatment with EGFR TKIs [21] or chemotherapy [22].
Moreover, it is also the strongest predictive factor for the efficacy
of EGFR TKIs [2], Similarly, in the current study, significantly
better response rates and survival results were noted in patients
with EGFR mutation, compared with those with EGFR status
unknown, in both first line and second/third lines subsets. Ren
Guanjun et al [23] analysed the relationship between EGFR
mutations and the efficacy of icotinib in patients enrolled in a
phase I study, the results showed that EGFR exon 19 deletions and
exon 21 point mutation are predictive biomarkers for response to
icotinib hydrochloride as second line or subsequent lines of
treatment. In the ICOGEN study, PFS and OS were longer in
patients with EGFR mutation (7.8 m and 20.9 m, respectively)
than those with EGFR mutation-negative (2.3 m and 7.8 m,
respectively). Thus, EGFR mutation status is the strongest
predictor in identifying which patients are most likely to benefit
from icotinib. Based on these results and previous evidence from
gefitinib and erlotinib, EGFR mutation should be detected when
considering the use of icotinib.
The adverse events in this study was similar with those observed
in ICOGEN study, while numerically less than those with gefitinib
[2,24,25] and erlotinib [6,26]. Although skin related events and
diarrhea were common, most of the events were grade 1, and no
patient needed dose reduction. However, the available data for
both the efficacy and safety of icotinib are limited, and more
studies are needed to address the role of icotinib in the treatment
Figure 2. Overall survival. 2–1 shows the OS in all patients in this
study, 2–2 shows the OS in first line subset, 2–3 shows the OS in
second/third line subset.
doi:10.1371/journal.pone.0095897.g002
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of non-small cell lung cancer. Besides the ICOGEN study, 13
prospective trials about icotinib are now active.
The key weakness of this report is its retrospective nature. The
evaluation of efficacy and toxicity was not predefined. Another
weakness is that the sample was small, especially for the first line
subset. In addition, only a small portion of patients had EGFR
status known both in first and second/third line.
In summary, a novel TKI, icotinib showed clinically meaningful
activity in the treatment of patients with lung adenocarcinoma,
especially in those patients harbouring EGFR mutations, with an
acceptable adverse event profile. The outcomes of the ongoing
trials on icotinib will give more evidence for the value of icotinib in
the treatment of NSCLC.
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